Measuring the influence of expectations, beliefs, and medication side effects on the risk for drug discontinuation among individuals starting new medications.
Blackburn, D.; Yao, S.; Taylor, J.; Al-Efan, Q.; Lix, L.; Eurich, D. T.; Choudhry, N. K.
Show abstract
ObjectivesTo measure the impact of beliefs, expectations, side effects, and their combined effects on the risk for medication non-persistence. DesignA population-based questionnaire. Setting and ParticipantsIndividuals from Saskatchewan, Canada who started a new antihypertensive, cholesterol-lowering, or antihyperglycemic medication were surveyed about risk factors for non-persistence including: (a) beliefs measured by a composite score of three questions asking about the threat of the condition, importance of the drug, and harm of the drug; (b) incident side effects attributed to treatment; and (c) expectations for side effects before starting treatment. Descriptive statistics and logistic regression models were used to quantify the influence of these risk factors on the outcome of non-persistence. Odds ratios (OR) and 95% confidence intervals (CI) were estimated. Main Outcome MeasureSelf-reported medication non-persistence. ResultsAmong 3,029 respondents, 5.9% (n=179) reported non-persistence within four months after starting the new drug. After adjustment for numerous covariates representing socio-demographics, healthcare providers, medication experiences and beliefs, both negative beliefs (OR 7.26, 95% CI: 4.98 to 10.59) and incident side effects (OR 8.00, 95% CI 5.49 to 11.68) were associated with the highest odds of non-persistence with no evidence of interaction. In contrast, expectations for side effects before starting treatment exhibited an important interaction with incident side effects following treatment initiation. Among respondents with incident side effects (n=741, 24.5%), the risk for early non-persistence was 11.5% if they indicated an expectation for side effects before starting the medication compared to 23.6% if they did not (adjusted OR 0.38, 95% CI 0.25 to 0.60). ConclusionsExpectations for side effects may be a previously unrecognized but important marker of the probability to persist with treatment. A high percentage of new medication users appeared unprepared for the possibility of side effects from their new medication making them less resilient if side effects occur. What is already known on this topicO_LIPrior expectations for side effects are thought to increase the risk for nocebo effects and increase the risk for medication non-persistence. C_LIO_LIMedication non-persistence remains a major threat to patient outcomes. C_LI What this study addsO_LIExpectations for side effects from medications may be a previously unrecognized protective factor against non-persistence. C_LIO_LIA high percentage of new medication users appear unprepared for the possibility of side effects from their new medication making them less resilient if side effects occur. C_LI
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Predicting intentions towards long-term antidepressant use in the management of people with depression in primary care: A longitudinal survey study 94%
- Assessment of knowledge and perception of prescribers towards rational medicine use in the Ashanti Region of Ghana 93%
- Effect of common maintenance drugs on the risk and severity of COVID-19 in elderly patients 93%
Similar papers in this journal
- Medication Clusters at Hospital Discharge and Risk of Adverse Drug Events at 30-days Post-Discharge: A Population-based Cohort Study of Older Adults 93%
- A comprehensive assessment of statin discontinuation among patients who concurrently initiate statins and CYP3A4-inhibitor drugs; a multistate transition model 93%
- Medication adherence and hospitalizations in older patients with coronary heart disease in Vietnam 91%
Similar papers in this journal
- Acute Pain Pathways: protocol for a prospective cohort study 92%
- A text messaging intervention to support patients with chronic pain during prescription opioid tapering: protocol for a double-blind randomised controlled trial 91%
- Evaluation of the General Practice Pharmacist (GPP) intervention to optimise prescribing in Irish primary care: a non-randomised pilot study 91%
Similar papers in this journal
- Practical barriers and facilitators experienced by patients, pharmacists and physicians to the implementation of pharmacogenomic screening in Dutch outpatient hospital care – an explorative pilot study 93%
- The Contribution of Pharmacogenetic Drug Interactions to 90-Day Hospital Readmissions: Preliminary Results from a Real-World Healthcare System 92%
- Pharmacogenomic and drug interaction risk associations with hospital length of stay among Medicare Advantage members with COVID-19 90%
Similar papers in this journal
- Association of patients’ past misdiagnosis experiences with trust in their current physician: the TRUMP 2 -Net study 91%
- Fentanyl initiation rate following the requirement for specialist approval 91%
- Barriers and Facilitators to Heart Failure Guideline-Directed Medical Therapy in an Integrated Health System and Federally-Qualified Health Centers: A Thematic Qualitative Analysis 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.